Strategic CDMO Diamond Animal Health positions itself as a contract development and manufacturing organization for USDA licensed biologicals and FDA registered pharmaceutical products for both large and small animals, offering a direct path for potential clients seeking development-to-market CDMO support.

Recent Partnerships Recent news shows active client onboarding with BiomEdit, Virbac collaboration to bring BOVIGEN Platinum to market, and sister-company alignment with Veterinary Pharmaceutical Solutions, indicating growing demand and potential cross-sell opportunities across animal health brands.

Acquisition Momentum The acquisition by Veterinary Pharmaceutical Solutions in 2023 and subsequent portfolio expansion in 2024 signal an enlarged platform for selling integrated manufacturing and development services to mid-market animal health companies.

Funding Signals Revenue in the $25–50M range with engagement from investment partners like Granite Creek Capital Partners suggests available capital for scaling manufacturing capacity, R&D tech investments, and expanded service offerings.

Industry Synergies Active involvement with notable players (Virbac, BiomEdit) and a broad tech stack including Salesforce, HubSpot, and WordPress indicates readiness for streamlined sales, CRM-driven outreach, and efficient account management to capture growth opportunities in both large and small animal segments.